International Clinical Trial: A single-arm, open-label, multicenter exploratory clinical trial of brentuximab vedotin combined with chidamide for the treatment of CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL) patients

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119766) titled 'A single-arm, open-label, multicenter exploratory clinical trial of brentuximab vedotin combined with chidamide for the treatment of CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL) patients' on March 3.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Huashan Hospital, Fudan University

Condition: Primary cutaneous T-cell lymphoma

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-03-03

Target Sample Size: Experimental group:33;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=308893

Publishe...